scholarly journals Evaluation of a retinal deep phenotyping platform to detect the likely cerebral amyloid PET status in humans

2020 ◽  
Vol 16 (S4) ◽  
Author(s):  
Jean‐Paul Soucy ◽  
Claudia Chevrefils ◽  
Sam Osseiran ◽  
Jean‐Philippe Sylvestre ◽  
Sylvain Beaulieu ◽  
...  
Keyword(s):  
Amyloid Pet ◽  
Cerebral Amyloid ◽  
Deep Phenotyping

scholarly journals A retinal deep phenotyping TM platform to predict the cerebral amyloid PET status in older adults

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Jean‐Paul Soucy ◽  
Claudia Chevrefils ◽  
Sam Osseiran ◽  
Jean‐Philippe Sylvestre ◽  
Frédéric Lesage ◽  
...  
Keyword(s):  
Older Adults ◽  
Amyloid Pet ◽  
Cerebral Amyloid ◽  
Deep Phenotyping

Amyloid-PET in cerebral amyloid angiopathy

Neurology ◽  
2017 ◽  
Vol 89 (14) ◽  
pp. 1437-1438 ◽  
Author(s):  
Nicolas Raposo ◽  
Joshua A. Sonnen
Keyword(s):  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Amyloid Pet ◽  
Cerebral Amyloid

scholarly journals Cerebral amyloid PET imaging in Alzheimer’s disease

2013 ◽  
Vol 126 (5) ◽  
pp. 643-657 ◽  
Author(s):  
Clifford R. Jack ◽  
Jorge R. Barrio ◽  
Vladimir Kepe
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Cerebral Amyloid ◽  
Amyloid Pet Imaging

IC-P-190: AN AMYLOID LIGAND-FREE OPTICAL RETINAL IMAGING METHOD TO PREDICT CEREBRAL AMYLOID PET STATUS

2006 ◽  
Vol 14 (7S_Part_2) ◽  
pp. P158-P158
Author(s):  
Jean-Paul Soucy ◽  
Claudia Chevrefils ◽  
Jean-Philippe Sylvestre ◽  
Jean Daniel Arbour ◽  
Marc-André Rhéaume ◽  
...  
Keyword(s):  
Retinal Imaging ◽  
Imaging Method ◽  
Amyloid Pet ◽  
Ligand Free ◽  
Cerebral Amyloid

Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation

2015 ◽  
Vol 50 (1) ◽  
pp. 1-7 ◽  
Author(s):  
María Carmona-Iragui ◽  
Ana Fernández-Arcos ◽  
Daniel Alcolea ◽  
Fabrizio Piazza ◽  
Estrella Morenas-Rodriguez ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Β ◽  
Amyloid Angiopathy ◽  
Amyloid Pet ◽  
Cerebral Amyloid

scholarly journals Diagnostic Utility of Amyloid PET in Cerebral Amyloid Angiopathy-Related Symptomatic Intracerebral Hemorrhage

2014 ◽  
Vol 34 (5) ◽  
pp. 753-758 ◽  
Author(s):  
Jean-Claude Baron ◽  
Karim Farid ◽  
Eamon Dolan ◽  
Guillaume Turc ◽  
Siva T Marrapu ◽  
...  
Keyword(s):  
Intracerebral Hemorrhage ◽  
Cerebral Amyloid Angiopathy ◽  
Visual Analysis ◽  
Diagnostic Value ◽  
Amyloid Angiopathy ◽  
Amyloid Pet ◽  
Healthy Elderly ◽  
Symptomatic Intracerebral Hemorrhage ◽  
Significant Difference ◽  
Cerebral Amyloid

By detecting β-amyloid ( Aβ) in the wall of cortical arterioles, amyloid positron emission tomography (PET) imaging might help diagnose cerebral amyloid angiopathy (CAA) in patients with lobar intracerebral hemorrhage (I-ICH). No previous study has directly assessed the diagnostic value of 11-Pittsburgh compound B (PiB) PET in probable CAA-related I-ICH against healthy controls (HCs). 11C-PiB-PET and magnetic resonance imaging (MRI) including T2* were obtained in 11 nondemented patients fulfilling the Boston criteria for probable CAA-related symptomatic I-ICH (sl-ICH) and 20 HCs without cognitive complaints or impairment. After optimal spatial normalization, cerebral spinal fluid (CSF)-corrected PiB distribution volume ratios (DVRs) were obtained. There was no significant difference in whole cortex or regional DVRs between CAA patients and age-matched HCs. The whole cortex DVR was above the 95% confidence limit in 4/9 HCs and 10/11 CAA patients (sensitivity = 91%, specificity = 55%). Region/frontal or occipital ratios did not have better discriminative value. Similar but less accurate results were found using visual analysis. In patients with sl-ICH, 11C-PiB-PET has low specificity for CAA due to the frequent occurrence of high 11C-PiB uptake in the healthy elderly reflecting incipient Alzheimer's disease (AD), which might also be present in suspected CAA. However, a negative PiB scan rules out CAA with excellent sensitivity, which has clinical implications for prognostication and selection of candidates for drug trials.

P2-252: AN AMYLOID LIGAND-FREE OPTICAL RETINAL IMAGING METHOD TO PREDICT CEREBRAL AMYLOID PET STATUS

2006 ◽  
Vol 14 (7S_Part_14) ◽  
pp. P771-P771 ◽  
Author(s):  
Jean-Paul Soucy ◽  
Claudia Chevrefils ◽  
Jean-Philippe Sylvestre ◽  
Jean Daniel Arbour ◽  
Marc-André Rhéaume ◽  
...  
Keyword(s):  
Retinal Imaging ◽  
Imaging Method ◽  
Amyloid Pet ◽  
Ligand Free ◽  
Cerebral Amyloid

P1-152: Augmenting amyloid PET interpretations with quantitative information improves consistency of cerebral amyloid detection

2015 ◽  
Vol 11 (7S_Part_8) ◽  
pp. P402-P403
Author(s):  
Jeffrey M. Burns ◽  
Eric D. Vidoni ◽  
Rasinio S. Graves ◽  
Jonathan Mahnken ◽  
Jacqueline D. Hill ◽  
...  
Keyword(s):  
Quantitative Information ◽  
Amyloid Pet ◽  
Cerebral Amyloid

Amyloid-PET in sporadic cerebral amyloid angiopathy

Neurology ◽  
2017 ◽  
Vol 89 (14) ◽  
pp. 1490-1498 ◽  
Author(s):  
Andreas Charidimou ◽  
Karim Farid ◽  
Jean-Claude Baron
Keyword(s):  
Diagnostic Accuracy ◽  
Cerebral Amyloid Angiopathy ◽  
Meta Analysis ◽  
Test Accuracy ◽  
Amyloid Angiopathy ◽  
Amyloid Pet ◽  
Case Control Studies ◽  
Amyloid A ◽  
Cerebral Amyloid ◽  
Good Diagnostic Accuracy

Objective:To perform a meta-analysis synthesizing evidence of the value and accuracy of amyloid-PET in diagnosing patients with sporadic cerebral amyloid angiopathy (CAA).Methods:In a PubMed systematic literature search, we identified all case-control studies with extractable data relevant for the sensitivity and specificity of amyloid-PET positivity in symptomatic patients with CAA (cases) vs healthy participants or patients with spontaneous deep intracerebral hemorrhage (ICH) (control groups). Using a hierarchical (multilevel) logistic regression model, we calculated pooled diagnostic test accuracy.Results:Seven studies, including 106 patients with CAA (>90% with probable CAA) and 151 controls, were eligible and included in the meta-analysis. The studies were of moderate to high quality and varied in several methodological aspects, including definition of PET-positive and PET-negative cases and relevant cutoffs. The sensitivity of amyloid-PET for CAA diagnosis ranged from 60% to 91% and the specificity from 56% to 90%. The overall pooled sensitivity was 79% (95% confidence interval [CI] 62–89) and specificity was 78% (95% CI 67–86) for CAA diagnosis. A predefined subgroup analysis of studies restricted to symptomatic patients presenting with lobar ICH CAA (n = 58 vs 86 controls) resulted in 79% sensitivity (95% CI 61–90%) and 84% specificity (95% CI 65–93%). In prespecified bivariate diagnostic accuracy meta-analysis of 2 studies using 18F-florbetapir-PET, the sensitivity for CAA-ICH diagnosis was 90% (95% CI 76–100%) and specificity was 88% (95% CI 74–100%).Conclusions:Amyloid-PET appears to have moderate to good diagnostic accuracy in differentiating patients with probable CAA from cognitively normal healthy controls or patients with deep ICH. Given that amyloid-PET labels both cerebrovascular and parenchymal amyloid, a negative scan might be useful to rule out CAA in the appropriate clinical setting.

Sign in / Sign up

Export Citation Format

Share Document